Engineering the perfect (bacterial) cancer therapy
Open accessThe DOI matches its Crossref record; 141 of the 141 references it cites were found in a registry or an index.
Abstract
Bacterial therapies possess many unique mechanisms for treating cancer that are unachievable with standard methods. Bacteria can specifically target tumours, actively penetrate tissue, are easily detected and can controllably induce cytotoxicity. Over the past decade, Salmonella, Clostridium and other genera have been shown to control tumour growth and promote survival in animal models. In this Innovation article I propose that synthetic biology techniques can be used to solve many of the key challenges that are associated with bacterial therapies, such as toxicity, stability and efficiency, and can be used to tune their beneficial features, allowing the engineering of 'perfect' cancer therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, in certain cases, injection of intratumoral bacteria or their antigens may conversely provide immunostimulatory effects, as demonstrated by Coley’s toxins and recent developments in bacterial cancer therapy (5, 105, 106).”
From The microbiome and human cancer (2021) · cites this paper as [105]
In the citing paper
“BCT is re-gaining attention through synthetic biology techniques that programmatically limit systemic toxicities while enhancing regional antitumor immunity (105, 106).”
From The microbiome and human cancer (2021) · cites this paper as [105]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guzman, L. M., Belin, D., Carson, M. J., & Beckwith, J. (1995) · Journal of Bacteriology · doi:10.1128/jb.177.14.4121-4130.1995 · Cited by 4,935
(1989) · PubMed · Cited by 3,343
Exploiting tumour hypoxia in cancer treatment
Brown, J. M., & Wilson, W. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1367 · Cited by 2,828
Drug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805 · cited 1×
“Many treatments, including chemotherapy and radiation, are toxic to normal tissue and cannot completely destroy all cancer cell”
BackgroundTumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.
Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., et al. (1999) · Nature Medicine · doi:10.1038/5517 · Cited by 2,497
Automated design of synthetic ribosome binding sites to control protein expression
Salis, H. M., Mirsky, E. A., & Voigt, C. A. (2009) · Nature Biotechnology · doi:10.1038/nbt.1568 · Cited by 1,844
CONTRIBUTION TO THE KNOWLEDGE OF SARCOMA
COLEY, W. B. (1891) · Annals of Surgery · doi:10.1097/00000658-189112000-00015 · Cited by 715
Toso, J. F. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.142 · Cited by 614 · cited 1×
“This containment is one possible reason that attenuated Salmonella had limited success in reducing tumour growth in human trial”
BackgroundCombination bacteriolytic therapy for the treatment of experimental tumors
Dang, L. H., Bettegowda, C., Huso, D. L., Kinzler, K. W., & Vogelstein, B. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251543698 · Cited by 563 · cited 1×
“For propulsion and sensing, bacteria have flagella that enable tissue penetratio”
BackgroundCombinatorial engineering of intergenic regions in operons tunes expression of multiple genes
Pfleger, B. F., Pitera, D. J., Smolke, C. D., & Keasling, J. D. (2006) · Nature Biotechnology · doi:10.1038/nbt1226 · Cited by 536 · cited 1×
“, including gene copy number, promoter strength, optimized codons, bacterial metabolism, mRNA secondary structur”
Background
Cited by
Items 101–200 of 905
Yamamoto, M., Zhao, M., Hiroshima, Y., Zhang, Y., Shurell, E., Eilber, F. C., Bouvet, M., Noda, M., & Hoffman, R. M. (2016) · PLOS ONE · doi:10.1371/journal.pone.0160882 · Cited by 102
Hiroshima, Y., Zhao, M. D., Maawy, A. A., Zhang, Y., Katz, M. H. G., Fleming, J. B., Uehara, F., Miwa, S., Yano, S., Momiyama, M., et al. (2014) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24769 · Cited by 102
Gupta, K. H., Nowicki, C. A., Giurini, E. F., Marzo, A. L., & Zloza, A. (2021) · Vaccines · doi:10.3390/vaccines9121497 · Cited by 120
“vasculature and penetrate hypoxic regions of the tumor [4] and subsequently proliferate within tumor cells [5].”
BackgroundFrahm, M., Felgner, S., Kocijancic, D., Rohde, M., Hensel, M., Curtiss, R., Erhardt, M., & Weiss, S. (2015) · mBio · doi:10.1128/mbio.00254-15 · Cited by 101
“Accordingly, Salmonella enterica serovar Typhimurium and Clostridium species have been intensively explored (9, 11, 12).”
BackgroundPharmaceutically controlled designer circuit for the treatment of the metabolic syndrome
Ye, H., Hamri, G. C., Zwicky, K., Christen, M., Folcher, M., & Fussenegger, M. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1216801110 · Cited by 113
“In recent years synthetic biology has greatly advanced the design of biomedical devices (19–22) that provide new diagnostic tools (23); offer novel concepts for the treatment of cancer (24, 25), immune diseases (26, 27), and diabetes (28); and pioneered prosthetic networks as a therapy for hyperuricemic disorders such…”
BackgroundSynthetic biology-inspired cell engineering in diagnosis, treatment and drug development
Zhao, N., Song, Y., Xie, X., Zhu, Z., Duan, C., Nong, C., Wang, H., & Bao, R. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01375-x · Cited by 121
“102,104 Cytolethal distending toxins from Salmonella typhi and the cycle-inhibiting factor (Cif) from enterohemorrhagic E. coli can inhibit cancer cell growth by blocking mitosis.”
BackgroundInfluentialBacteria and bacterial derivatives as delivery carriers for immunotherapy
Kang, S., Nguyen, D.-H., Yoo, S. W., & Min, J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114085 · Cited by 106
Biomaterial‐Based In Situ Cancer Vaccines
Yang, B., & Wang, H. (2023) · Advanced Materials · doi:10.1002/adma.202210452 · Cited by 105
Cuproptosis: mechanisms and nanotherapeutic strategies in cancer and beyond
Mao, L., Lu, J., Wen, X., Song, Z., Sun, C., Zhao, Y., Huang, F., Chen, S., Jiang, D., Che, W., et al. (2025) · Chemical Society Reviews · doi:10.1039/d5cs00083a · Cited by 109
The spontaneous remission of cancer: Current insights and therapeutic significance
Radha, G., & Lopus, M. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101166 · Cited by 116
Promising dawn in tumor microenvironment therapy: engineering oral bacteria
Wang, Z., Sun, W., Hua, R., Wang, Y., Li, Y., & Zhang, H. (2024) · International Journal of Oral Science · doi:10.1038/s41368-024-00282-3 · Cited by 97
“12,13 More importantly, the remarkable capability of unlimited gene packaging enables recombinant bacteria to express and deliver a diverse range of therapeutic payloads, including chimeric toxins, cytokines, prodrug-converting enzymes, immunomodulators, and angiogenesis modulators for combating…”
BackgroundOral delivery of bacteria: Basic principles and biomedical applications
Li, S., Jiang, W., Zheng, C., Shao, D., Liu, Y., Huang, S., Han, J., Ding, J., Tao, Y., & Li, M. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.09.011 · Cited by 97
Mechanisms of cooperation in cancer nanomedicine: towards systems nanotechnology
Hauert, S., & Bhatia, S. N. (2014) · Trends in biotechnology · doi:10.1016/j.tibtech.2014.06.010 · Cited by 112
“Lessons learned from the design of cooperative nanosystems could also prove useful in the engineering of natural swarmers, such as cells of the immune system [41] or synthetic bacteria [42], to improve tumor treatment and diagnostics.”
Targeted Cancer Therapy Using Engineered Salmonella typhimurium
Zheng, J. H., & Min, J.-J. (2016) · Chonnam Medical Journal · doi:10.4068/cmj.2016.52.3.173 · Cited by 95
“typhimurium have unique properties that can overcome these limitations: (1) the ability to sense and target tumors, (2) preferential growth in a tumor-specific microenvironment, (3) good intratumoral penetration, (4) low cytotoxicity and immunogenicity, and (5) versatile programmability.(29) Salmonellae can be enginee…”
BackgroundNear‐Infrared Nano‐Optogenetic Activation of Cancer Immunotherapy via Engineered Bacteria
Zhu, X., Chen, S., Hu, X., Zhao, L., Wang, Y., Huang, J., Chen, J., Qiu, Y., Zhang, X., Wang, M., et al. (2022) · Advanced Materials · doi:10.1002/adma.202207198 · Cited by 103
St. Jean, A. T., Swofford, C. A., Panteli, J. T., Brentzel, Z. J., & Forbes, N. S. (2014) · Molecular Therapy · doi:10.1038/mt.2014.36 · Cited by 92
Self-citationBiodegradable Small‐Scale Swimmers for Biomedical Applications
Llacer‐Wintle, J., Rivas‐Dapena, A., Chen, X., Pellicer, E., Nelson, B. J., Puigmartí‐Luis, J., & Pané, S. (2021) · Advanced Materials · doi:10.1002/adma.202102049 · Cited by 91
Flentie, K., Kocher, B. A., Gammon, S. T., Novack, D. V., McKinney, J. S., & Piwnica-Worms, D. R. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0201 · Cited by 94
“Indeed, Salmonella have been used as tumorspecifi c vectors for gene transfer of RNA interference or suicide genes, as well as targeted expression of apoptosis-inducing biologics, such as TRAIL, FASL, and the bacterial toxin, cytolysin A, all of which display pronounced antitumor effects in vivo (5).”
InfluentialLive-attenuated bacteria as a cancer vaccine vector
Toussaint, B., Chauchet, X., Wang, Y., Polack, B., & Gouëllec, A. L. (2013) · Expert Review of Vaccines · doi:10.1586/14760584.2013.836914 · Cited by 91
Enzyme/Prodrug Systems for Cancer Gene Therapy
Malekshah, O. M., Chen, X., Nomani, A., Sarkar, S., & Hatefi, A. (2016) · Current Pharmacology Reports · doi:10.1007/s40495-016-0073-y · Cited by 96
“For more information related to the use of vectors for cancer gene therapy, the readers are referred to excellent recent reviews by Forbes [27], Cattaneo et al. [11], and Mohit and Rafati [63].”
MethodPD-1-siRNA delivered by attenuated Salmonella enhances the antimelanoma effect of pimozide
Zhao, T., Wei, T., Guo, J., Wang, Y., Shi, X., Guo, S. J., Jia, X., Jia, H., & Feng, Z. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1418-3 · Cited by 88
Clostridium novyi-NT can cause regression of orthotopically implanted glioblastomas in rats
Staedtke, V., Bai, R.-Y., Sun, W., Huang, J., Kibler, K. K., Tyler, B. M., Gallia, G. L., Kinzler, K., Vogelstein, B., Zhou, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3627 · Cited by 89
“Various species of Clostridium, Salmonella, Escherichia, Bifidobacterium and Listeria have all been considered for this purpose [8].”
BackgroundInfluentialMicroencapsulation for Pharmaceutical Applications: A Review
Yan, C., & Kim, S.-R. (2024) · ACS Applied Bio Materials · doi:10.1021/acsabm.3c00776 · Cited by 109
Synthetic biology for pharmaceutical drug discovery
Trosset, J., & Carbonell, P. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s58049 · Cited by 104
“190,191 The design principles and generation of novel signaling properties have been reviewed by Furukawa and Hohmann in the context of engineered yeast mitogen-activated protein kinase pathways.”
Bacteria and bacterial anticancer agents as a promising alternative for cancer therapeutics
Baindara, P., & Mandal, S. M. (2020) · Biochimie · doi:10.1016/j.biochi.2020.07.020 · Cited by 92
Liu, Y., Zhang, M., Wang, X., Yang, F., Cao, Z., Wang, L., & Liu, J. (2022) · Advanced Materials · doi:10.1002/adma.202210949 · Cited by 91
Biomineralization of Bacteria by a Metal–Organic Framework for Therapeutic Delivery
Yan, S., Zeng, X., Wang, Y., & Liu, B. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.202000046 · Cited by 81
Intratumor microbiome in cancer progression: current developments, challenges and future trends
Liu, J., & Zhang, Y. (2022) · Biomarker Research · doi:10.1186/s40364-022-00381-5 · Cited by 80
“Regulating bacterial gene expression might further modulate the accumulation of anti-tumor payloads at tumor sites and control continuous drug delivery [132].”
BackgroundEngineering Bacteria and Bionic Bacterial Derivatives with Nanoparticles for Cancer Therapy
Yin, T., Diao, Z., Blum, N. T., Qiu, L., Ma, A.-Q., & Huang, P. (2021) · Small · doi:10.1002/smll.202104643 · Cited by 85
Bacterially mediated drug delivery and therapeutics: Strategies and advancements
Wu, L., Bao, F., Li, L., Yin, X., & Hua, Z. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114363 · Cited by 83
Sokolov, I. L., Cherkasov, V. R., Tregubov, A. A., Buiucli, S., & Nikitin, M. P. (2017) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2017.01.027 · Cited by 85
Kaimala, S., Mohamed, Y. A., Nader, N., Issac, J. M., Elkord, E., Chouaïb, S., Fernández-Cabezudo, M. J., & al-Ramadi, B. K. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1543-x · Cited by 89
Jeong, J.-H., Kim, K., Lim, D., Jeong, K., Hong, Y., Nguyen, V. H., Kim, T.-H., Ryu, S., Lim, J.-A., Kim, J. I., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0080050 · Cited by 79
Technical guide for genetic advancement of underdeveloped and intractable Clostridium
Pyne, M. E., Bruder, M., Moo-Young, M., Chung, D. A., & Chou, C. P. (2014) · Biotechnology Advances · doi:10.1016/j.biotechadv.2014.04.003 · Cited by 78
Chen, J., Qiao, Y., Chen, G., Chang, C., Dong, H., Tang, B., Cheng, X., Liu, X., & Hua, Z. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.04.019 · Cited by 83
Binder, D. C., Engels, B., Arina, A., Yu, P., Slauch, J. M., Fu, Y.-X., Karrison, T., Burnette, B., Idel, C., Zhao, M., et al. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0058 · Cited by 78
“Typhimurium strains preferentially accumulate in murine tumors (for review see (23)) and reduce immunosuppression in the tumor and tumor-draining lymph node (24, 25).”
BackgroundSalmonella -Mediated Cancer Therapy: An Innovative Therapeutic Strategy
Mi, Z., Feng, Z., Li, C., Yang, X. H., Ma, M., & Rong, P. (2019) · Journal of Cancer · doi:10.7150/jca.32650 · Cited by 83
“Immunotherapy based on Salmonella has a specific "Trojan horse" tumor-attack feature, which has been used in treatment-resistant tumors [15-17].”
BackgroundGniadek, T. J., Augustin, L. B., Schottel, J. L., Leonard, A. S., Saltzman, D. A., Greeno, E. W., & Batist, G. (2020) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000325 · Cited by 77
Heap, J. T., Theys, J., Ehsaan, M., Kubiak, A. M., Dubois, L. J., Paesmans, K., Mellaert, L. V., Knox, R. J., Kuehne, S. A., Lambin, P., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1761 · Cited by 94
“The use of elegant synthetic regulatory mechanisms has also been proposed for containment [4] but we are cautious of their use for this purpose, and suggest that physiological mechanisms may be more appropriate.”
Engineering Salmonella as intracellular factory for effective killing of tumour cells
Camacho, E. M., Mesa-Pereira, B., Medina, C., Flores, A., & Santero, E. (2016) · Scientific Reports · doi:10.1038/srep30591 · Cited by 77
Emerging applications of bacteria as antitumor agents
Kalia, V. C., Patel, S. K. S., Cho, B., Wood, T. K., & Lee, J.-K. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.05.012 · Cited by 81
Li, W.-Q., Wang, Z., Hao, S., Sun, L., Nisic, M., Cheng, G., Zhu, C., Wan, Y., Ha, L., & Zheng, S.-Y. (2018) · Nanoscale · doi:10.1039/c7nr08816g · Cited by 80
The role of bacterial toxins and spores in cancer therapy
Weerakkody, L. R., & Witharana, C. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116839 · Cited by 75
Kojima, R., Aubel, D., & Fussenegger, M. (2015) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2015.05.021 · Cited by 79
Expressing cytotoxic compounds in Escherichia coli Nissle 1917 for tumor-targeting therapy
Li, R., Helbig, L., Fu, J., Bian, X., Herrmann, J., Baumann, M., Stewart, A. F., Müller, R., Li, A., Zips, D., et al. (2019) · Research in Microbiology · doi:10.1016/j.resmic.2018.11.001 · Cited by 73
Nano-and Micromotors Designed for Cancer Therapy
Sonntag, L., Simmchen, J., & Magdanz, V. (2019) · Molecules · doi:10.3390/molecules24183410 · Cited by 77
“typhimurium are known to accumulate and replicate in solid tumors [184].”
BackgroundInfluence of gut and intratumoral microbiota on the immune microenvironment and anti-cancer therapy
Chen, Y., Liu, B., Wei, Y., & Kuang, D.-M. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105966 · Cited by 73
Breast cancer vaccines: New insights into immunomodulatory and nano-therapeutic approaches
Davodabadi, F., Sarhadi, M., Arabpour, J., Sargazi, S., Rahdar, A., & Diez-Pascual, A. M. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.07.036 · Cited by 85
Bacteria‐Based Materials for Stem Cell Engineering
Hay, J. J., Rodrigo‐Navarro, A., Petaroudi, M., Bryksin, A. V., García, A. J., Barker, T. H., Dalby, M. J., & Salmerón‐Sánchez, M. (2018) · Advanced Materials · doi:10.1002/adma.201804310 · Cited by 73
Microbes as Medicines: Harnessing the Power of Bacteria in Advancing Cancer Treatment
Sawant, S. S., Patil, S. M., Gupta, V., & Kunda, N. K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207575 · Cited by 78
“The protein expression was evidently seen only in the tumor tissues and not in healthy tissues and no expression was seen in case where the distance between the bacterial colonies was greater than 155 mm [75].”
BackgroundRuan, Y., Zhuang, H., Zeng, X., Lin, L., Wang, X., Xue, P., Xu, S., Chen, Q., Yan, S., & Huang, W. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202302537 · Cited by 83
Xiong, M., Bao, Y., Du, X., Tan, Z., Jiang, Q., Wang, H., Zhu, Y., & Wang, J. (2013) · ACS Nano · doi:10.1021/nn403146t · Cited by 72
Towards a Synthetic Chloroplast
Agapakis, C. M., Niederholtmeyer, H., Noche, R. R., Lieberman, T. D., Megason, S. G., Way, J. C., & Silver, P. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018877 · Cited by 77
Genetically Engineered Cellular Membrane Vesicles as Tailorable Shells for Therapeutics
Ren, E., Liu, C., Lv, P., Wang, J., & Liu, G. (2021) · Advanced Science · doi:10.1002/advs.202100460 · Cited by 76
Delivering living medicines with biomaterials
Harimoto, T., Jung, W., & Mooney, D. J. (2025) · Nature Reviews Materials · doi:10.1038/s41578-024-00766-y · Cited by 89
“For example, several types of bacteria have been demonstrated to colonize the immunosuppressive solid tumour environment, but potential bacteria dissemination leading to secondary infections remains a major concern 50–52”
Anti-tumor activity of an immunotoxin (TGFα-PE38) delivered by attenuated Salmonella typhimurium
Lim, D., Kim, K. S., Kim, H., Ko, K., Song, J., Choi, J. H., Shin, M., Min, J., Jeong, J., & Choy, H. E. (2017) · Oncotarget · doi:10.18632/oncotarget.17197 · Cited by 74
“It was suggested that tumor tissue provides an immunoprivileged environment, indeed a sanctuary, for intratumoral bacteria, which can then proliferate to yield up to 109 CFU g-1 tissue [46, 48].”
Synthetic therapeutic gene circuits in mammalian cells
Ye, H., & Fussenegger, M. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.05.003 · Cited by 76
Advances in Salmonella Typhimurium-based drug delivery system for cancer therapy
Chen, W., Zhu, Y., Zhang, Z., & Sun, X. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114295 · Cited by 68
Autonomous bacterial localization and gene expression based on nearby cell receptor density
Wu, H., Tsao, C., Quan, D. N., Cheng, Y., Servinsky, M. D., Carter, K. K., Jee, K. J., Terrell, J. L., Zargar, A., Rubloff, G. W., et al. (2013) · Molecular Systems Biology · doi:10.1038/msb.2012.71 · Cited by 74
“Several studies have demonstrated the use of bacteria for both the synthesis and delivery of proteins or other toxins in cancer models (Forbes, 2010).”
InfluentialDiscovery of Intratumoral Oncolytic Bacteria Toward Targeted Anticancer Theranostics
Goto, Y., Iwata, S., Miyahara, M., & Miyako, E. (2023) · Advanced Science · doi:10.1002/advs.202301679 · Cited by 81
Prosser, G. A., Copp, J. N., Mowday, A. M., Guise, C. P., Syddall, S. P., Williams, E. M., Horvat, C. N., Swe, P. M., Ashoorzadeh, A., Denny, W. A., et al. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.01.029 · Cited by 69
Salmonella and cancer: from pathogens to therapeutics.
Chorobik, P., Czaplicki, D., Ossysek, K., & Bereta, J. (2013) · Acta Biochimica Polonica · doi:10.18388/abp.2013_1984 · Cited by 68
Strains, Mechanism, and Perspective:Salmonella-Based Cancer Therapy
Wang, C., Kazmierczak, R. A., & Eisenstark, A. (2016) · International Journal of Microbiology · doi:10.1155/2016/5678702 · Cited by 79
“Some cytotoxic agents, cytokines, and tumor antigens have been designed to be expressed in tumor cells by Salmonella transfection [42].”
BackgroundAutonomous bacterial nanoswimmers target cancer
Zoaby, N., Shainsky-Roitman, J., Badarneh, S., Abumanhal, H., Leshansky, A., Yaron, S., & Schroeder, A. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.10.006 · Cited by 68
Optimization of Nanoparticles for Smart Drug Delivery: A Review
Jia, L., Zhang, P., Sun, H., Dai, Y., Liang, S., Bai, X., & Feng, L. P. (2021) · Nanomaterials · doi:10.3390/nano11112790 · Cited by 76
“Bacteria have unique abilities that make them suitable as “small doctors”: they are self-driven (they can penetrate hard-to-reach tumor sites) and able to sense the local environment in response to external signals [133].”
BackgroundLiving Bacteria in Thermoresponsive Gel for Treating Fungal Infections
Lufton, M., Bustan, O., Eylon, B., Shtifman‐Segal, E., Croitoru‐Sadger, T., Shagan, A., Shabtay‐Orbach, A., Corem‐Salkmon, E., Berman, J. G., Nyska, A., et al. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201801581 · Cited by 66
Chen, M., Han, Q., Zhang, M., Liu, Y., Wang, L., Yang, F., Li, Q., Cao, Z., Fan, C., & Liu, J. (2024) · Science Advances · doi:10.1126/sciadv.adk9485 · Cited by 67
Felgner, S., Kocijancic, D., Frahm, M., Heise, U., Rohde, M., Zimmermann, K., Falk, C. S., Erhardt, M., & Weiß, S. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1382791 · Cited by 70
“(iii) Because of an intrinsic tumor colonizing ability, engineered bacteria could be exploited as tumor targeting vectors for delivery of genetic cargo.(2,15,16) Despite these advantages, the immune system of the host could represent a major obstacle for BMTT.”
BackgroundMagnetotactic bacteria for cancer therapy
Fdez-Gubieda, M. L., Alonso, J. A., García-Prieto, A., García-Arribas, A., Barquín, L. F., & Muela, A. (2020) · Journal of Applied Physics · doi:10.1063/5.0018036 · Cited by 70
Engineering of bacterial strains and their products for cancer therapy
Bernardes, N., Chakrabarty, A. M., & Fialho, A. M. (2013) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-013-4926-6 · Cited by 70
Bacteria and cancer: Different sides of the same coin
Laliani, G., Sorboni, S. G., Lari, R., Yaghoubi, A., Soleimanpour, S., Khazaei, M., Hasanian, S. M., & Avan, A. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117398 · Cited by 71
Cancer-cell killing by engineered Salmonella imaged by multiphoton tomography in live mice.
Uchugonova, A., Zhao, M. D., Zhang, Y., Weinigel, M., König, K., & Hoffman, R. M. (2012) · PubMed · Cited by 65
The Role of The Tumor Microbiome in Tumor Development and Its Treatment
Chen, Y., Wu, F., Wu, P., Xing, H., & Ma, T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.935846 · Cited by 77
“There are three main types of bacterial anticancer agents: cytotoxic agents that kill cancer cells directly, cytokines that stimulate immune cells to kill cancer cells, and tumor antigens that sensitize the immune system to cancer cells (131).”
BackgroundBacteria as Nanoparticles Carrier for Enhancing Penetration in a Tumoral Matrix Model
Moreno, V., Álvarez, E., Izquierdo‐Barba, I., Baeza, A., Serrano‐López, J., & Vallet‐Regí, M. (2020) · Advanced Materials Interfaces · doi:10.1002/admi.201901942 · Cited by 75
Bacteria-Inspired Nanomedicine
Holay, M., Guo, Z., Pihl, J., Heo, J., Park, J. H., Fang, R. H., & Zhang, L. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c01072 · Cited by 64
Cell-mediated and cell membrane-coated nanoparticles for drug delivery and cancer therapy
Yaman, S., Chintapula, U. K., Rodriguez, E., Ramachandramoorthy, H., & Nguyen, K. T. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.55 · Cited by 82
“The use of bacterial cell-mediated drug delivery may induce unfavorable immune responses in immune compromised terminally ill cancer patients[37].”
BackgroundDirect Injection of Functional Single-Domain Antibodies from E. coli into Human Cells
Blanco‐Toribio, A., Muyldermans, S., Frankel, G. M., & Fernández, L. Á. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015227 · Cited by 68
McNerney, M. P., Watstein, D. M., & Styczynski, M. P. (2015) · Metabolic Engineering · doi:10.1016/j.ymben.2015.06.011 · Cited by 68
“Bacteria can be programmed to release cytotoxic agents, cytokines, or tumor antigens in the presence of the tumor, but suboptimal targeting efficiency and intrinsic bacterial toxicity have limited their use as clinical therapeutics (Forbes, 2010).”
BackgroundBacterial Signaling at the Intestinal Epithelial Interface in Inflammation and Cancer
Coleman, O. I., & Haller, D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01927 · Cited by 77
“Injection of specific bacteria into tumor tissue may help eradicate tumors through the stimulation of inflammation and anti-tumor responses (153).”
BackgroundDual drugs decorated bacteria irradiate deep hypoxic tumor and arouse strong immune responses
Chen, W., He, C., Qiao, N., Guo, Z., Hu, S., Song, Y., Wang, H., Zhang, Z., Ke, B., & Sun, X. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121582 · Cited by 68
Synthetic Genomics and Synthetic Biology Applications Between Hopes and Concerns
König, H., Frank, D. O., Heil, R., & Coenen, C. (2013) · Current Genomics · doi:10.2174/1389202911314010003 · Cited by 83
“For example, bacterial toxicity or host immune response to bacteria and viruses may occur, or there may be genetic changes with unpredictable consequences during the proliferation cycle of “living therapeutics” such as viruses or bacteria [97, 98].”
BackgroundZhou, X. W., Ling, K., Liu, M., Zhang, X., Ding, J., Dong, Y., Liang, Z., Li, J., & Zhang, J. (2019) · Theranostics · doi:10.7150/thno.35353 · Cited by 66
“In these cases, bacteria and yeast cells as well as their bioengineered products were investigated as either therapeutics or delivery carriers [59-61].”
BackgroundPanagioti, E., Kurokawa, C., Viker, K., Ammayappan, A., Anderson, S. K., Sotiriou, S., Chatzopoulos, K., Ayasoufi, K., Johnson, A. J., Iankov, I. D., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci141614 · Cited by 71
“Preliminary evidence suggests that combined administration of OVs and bacterial components can enhance induction of antitumor responses (15, 16).”
BackgroundRecent advances in bacteria-mediated cancer therapy
Liang, S., Wang, C., Shao, Y., Wang, Y., Xing, D., & Geng, Z. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.1026248 · Cited by 71
“…their genetics can be simply modified to produce and release specific compounds, which can combine with the production of specific toxins to stimulate an effective immune response, which leads to tumor regression (Forbes, 2010; Danino et al., 2015; Kucerova and Cervinkova, 2016; Xu et al., 2018).”
BackgroundCampylobacter jejuni-derived cytolethal distending toxin promotes colorectal cancer metastasis
He, Z., Yu, J., Gong, J., Wu, J., Zong, X., Luo, Z., He, X., Cheng, W. M., Liu, Y., Liu, C., et al. (2024) · Cell Host & Microbe · doi:10.1016/j.chom.2024.11.006 · Cited by 72
In Vivo Gene Expression Dynamics of Tumor-Targeted Bacteria
Danino, T., Lo, J., Prindle, A., Hasty, J., & Bhatia, S. N. (2012) · ACS Synthetic Biology · doi:10.1021/sb3000639 · Cited by 61
“safety and tolerance in human clinical trials ([25],[5],[22],[8]).”
Matsumoto, Y., Miwa, S., Zhang, Y., Zhao, M. D., Yano, S., Uehara, F., Yamamoto, M., Hiroshima, Y., Toneri, M., Bouvet, M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3607 · Cited by 61
“The barriers in tumors for standard therapy such as hypoxia, acidic pH, disorganized vascular architecture, are beneficial for bacteria to target cancer [7].”
BackgroundAllemailem, K. S. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s338272 · Cited by 67
“coli, as facultative anaerobes, can sense the nutrient-rich and favorable environment through their chemoreceptors and get accumulated in the periphery as well as the core of tumor region.(13) Bacteria preferably colonize in these regions as it displays an immunosuppressive environment, so is not usually cleared by ne…”
InfluentialECM-targeting bacteria enhance chemotherapeutic drug efficacy by lowering IFP in tumor mouse models
Kim, J.-S., Park, J.-E., Choi, S.-H., Kang, S. W., Lee, J. H., Lee, J.-S., Shin, M., & Park, S.-H. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.02.001 · Cited by 61
Qin, S., Liu, Y., He, G., Yang, H. J., Zeng, F., Lu, Q., Wang, M., He, B., & Song, Y. (2024) · ACS Nano · doi:10.1021/acsnano.4c08117 · Cited by 66
Chromosome-free bacterial cells are safe and programmable platforms for synthetic biology
Fan, C., Davison, P. A., Habgood, R., Zeng, H., Decker, C. M., Gesell Salazar, M., Lueangwattanapong, K., Townley, H. E., Yang, A., Thompson, I. P., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1918859117 · Cited by 60
“As it is known that some bacteria preferentially associate with tumors (10), synthetic biology tools and concepts can be used to further engineer bacteria to sense, target, and deliver anticancer compounds locally to tumors (11–14).”
Tumor-targetingSalmonella typhimuriumA1-R arrests growth of breast-cancer brain metastasis
Zhang, Y., Miwa, S., Zhang, N., Hoffman, R. M., & Zhao, M. D. (2014) · Oncotarget · doi:10.18632/oncotarget.2811 · Cited by 60
“Anaerobic bacteria must be used in combination with chemotherapy to be effective [4, 5].”
BackgroundBacteria-mediated cancer therapies: opportunities and challenges
Yang, M., Yang, F., Chen, W., Liu, S., Qiu, L., & Chen, J. (2021) · Biomaterials Science · doi:10.1039/d1bm00634g · Cited by 62
Reprogramming the tumor immune microenvironment using engineered dual-drug loaded Salmonella
Nguyen, D.-H., You, S.-H., Ngo, H. T.-T., Nguyen, K. V., Tran, K. V., Chu, T.-H., Kim, S.-Y., Ha, S., Hong, Y., & Min, J. (2024) · Nature Communications · doi:10.1038/s41467-024-50950-5 · Cited by 78
“Attenuated Salmonella are the most studied bacterial species in the context of anti-cancer therapy 21,29 .”
Targeting Tumors with Salmonella Typhimurium - Potential for Therapy
Wall, D. M., Srikanth, C. V., & McCormick, B. A. (2010) · Oncotarget · doi:10.18632/oncotarget.206 · Cited by 69
“Bacteria have been recently described as “tiny programmable robot factories” for use in cancer therapy [25].”
BackgroundImaging of tumor colonization by Escherichia coli using 18F-FDS PET
Kang, S., Jo, E. J., Nguyen, V. H., Zhang, Y., Yoon, H. S., Pyo, A., Kim, D.-Y., Hong, Y., Bom, H., & Min, J. (2020) · Theranostics · doi:10.7150/thno.42121 · Cited by 60
“coli was heterogeneous, which is not surprising because bacterial localization to tumors is known to be heterogeneous [1].”
BackgroundTumor-targeting bacterial therapy: A potential treatment for oral cancer (Review)
LIU, S., Xu, X., Zeng, X. Y., Li, L., Chen, Q., & LI, J. (2014) · Oncology Letters · doi:10.3892/ol.2014.2525 · Cited by 65
“Bacteria may be detected using light, MRI or positron emission tomography (28,29).”
The intratumoral microbiome: Characterization methods and functional impact
Heymann, C. J. F., Bard, J.-M., Heymann, M.-F., Heymann, D., & Bobin-Dubigeon, C. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.09.009 · Cited by 57
Tumor-seeking Salmonella amino acid auxotrophs
Hoffman, R. M. (2011) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2011.03.009 · Cited by 62
Tools and applications in synthetic biology
MacDonald, I. C., & Deans, T. L. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.08.008 · Cited by 70
Metadata
- Authors
- Forbes, N. S.
- Affiliations
- University of Massachusetts Amherst (US)
- Corresponding author
- Forbes, Neil S.
- ORCID
- Forbes, Neil S.
- Venue
- Nature Reviews Cancer
- Published
- 2010-10-14
- Volume
- 10
- Issue
- 11
- Pages
- 785-794
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC3756932
- OpenAlex
- W1979507175
- Cited by
- 905
- References
- 141
- Citations by year
- 2026: 76 · 2025: 89 · 2024: 95 · 2023: 76 · 2022: 81 · 2021: 81 · 2020: 69 · 2019: 47 · 2018: 47 · 2017: 46 · 2016: 42 · 2015: 40 · 2014: 45 · 2013: 37 · 2012: 20
- FWCI
- 2.44
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA120825, CA120825)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Bacterial Genetics and Biotechnology
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Keywords
- bacterial cancer therapy, synthetic biology, Salmonella, Clostridium, tumor targeting, bacterial cytotoxicity, bacterial stability, bacterial toxicity, tumor growth control, cancer immunotherapy
- MeSH terms
- Animals, Antineoplastic Agents, Clostridium, Genetic Engineering, Humans, Neoplasms, Salmonella
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.